Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell

Related Experiment Video

Updated: Aug 7, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Alissa K Greenberg1, Jing Hu, Sharmila Basu

  • 1Department of Medicine, New York University School of Medicine, New York 10016, USA. alissa.greenberg@med.nyu.edu

American Journal of Respiratory Cell and Molecular Biology
|September 3, 2002
PubMed

Insights

Dexamethasone inhibits non-small cell lung cancer growth by arresting the cell cycle. This occurs via the extracellular signal-related kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway, offering insights into glucocorticoid-induced growth inhibition.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Glucocorticoids are known to inhibit cell proliferation, but the precise molecular mechanisms are not fully understood.
  • Non-small cell lung cancer (NSCLC) remains a significant health concern, necessitating research into novel therapeutic targets and mechanisms of growth inhibition.

Purpose of the Study:

  • To elucidate the mechanism by which dexamethasone, a synthetic glucocorticoid, inhibits the proliferation and cell cycle progression of non-small cell lung cancer cells.
  • To investigate the role of the extracellular signal-related kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling pathway in dexamethasone-induced growth inhibition.

Main Methods:

  • Utilized fluorescence-activated cell sorter (FACS) analysis to assess cell cycle distribution.
  • Employed Western blot analysis to evaluate protein levels and phosphorylation states, including retinoblastoma protein, cyclins, E2F, Myc, and p21(Cip1).
  • Performed in vitro kinase assays to determine the activity of cyclin-dependent kinases (CDKs) and the ERK/MAPK pathway.

Main Results:

  • Dexamethasone treatment led to the suppression of proliferation in A549 and Calu-1 NSCLC cells, with a notable accumulation of cells in the G1/G0 phase.
  • Observed hypophosphorylation of retinoblastoma protein, decreased activity of CDK2 and CDK4, reduced levels of cyclin D, E2F, and Myc, and increased levels of the CDK inhibitor p21(Cip1).
  • Demonstrated that dexamethasone decreases the activity of the ERK/MAPK pathway, and the timing of these changes suggests this inhibition precedes cell cycle arrest.

Conclusions:

  • Dexamethasone effectively inhibits non-small cell lung cancer cell proliferation and induces cell cycle arrest at the G1/G0 stage.
  • The findings suggest that the inhibition of the ERK/MAPK signaling pathway is a key mechanism underlying glucocorticoid-induced cell cycle arrest and growth inhibition in NSCLC.
  • This study provides a potential alternative mechanism for glucocorticoid action, highlighting the role of MAPK signaling in cancer growth regulation.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...